ProMIS Neurosciences Inc.'s (PMN:TSX; ARFXF:OTCQB) lead therapeutic candidate for Alzheimer's disease, PMN310, will be evaluated in a Phase 1b clinical trial in early 2023, Argus Research analyst Steve Silver reported in a June 27 note. PMN310 is a monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of amyloid-beta, a recognized root cause of Alzheimer's disease.
"We estimate that more than 100 candidates for Alzheimer's disease are currently in the clinic and view PMN310 as potentially representing a best-in-class opportunity," Silver wrote.
The upcoming Phase 1b study, Silver relayed, will be open-label and dose ascending. Safety and efficacy will be assessed. The trial will be conducted at five to eight sites, allowing for quick enrollment.
ProMIS has a competitive edge with PMN310 and its scientific platform, Silver highlighted.
With the latter, the company can develop selective antibody therapies against toxic oligomers that result from misfolded proteins associated with the development and progression of certain neurodegenerative diseases.
"ProMIS' approach is validated and differentiated from other treatments and technologies in development due to its accuracy of computational modeling and artificial intelligence that enable the generation of therapeutic antibodies that are highly selective for toxic misfolded proteins and not their normal, physiological forms," Silver wrote.
The neurodegenerative diseases market, Silver pointed out, is "extremely attractive" and "among the largest areas of unmet needs across the entire biopharmaceutical industry."
To move forward with the Phase 1b study, ProMIS has been preparing to file an investigational new drug application for PMN310. As part of that, among other efforts, high-concentration formulations of the antibody, which can support subcutaneous dosing, are being developed. That work is expected to be finished soon.
Silver noted that beyond PMN310, the biotech firm is developing PMN267 as its lead product candidate for the treatment of amyotrophic lateral sclerosis (ALS). Findings so far are encouraging.
"To date, an intrabody version of PMN267, delivered inside cells via a gene therapy vector, has shown significant reductions in the amount of TDP-43 aggregates in human motor neurons derived from ALS patients, and an injectable antibody treatment has produced promising trends for protection against disability," Silver explained.
Looking forward, Silver expects ProMIS to continue executing its development strategy. Also, it may uplist its U.S. stock to the NASDAQ and capitalize on opportunities to partner with Big Pharma on any of its product candidates.
Disclosures:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences Inc. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences Inc., a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
